The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia
Open accessAbstract
A multicenter investigation of allogeneic bone marrow transplantation for children with sickle cell disease was conducted that included 27 European and North American transplant centers. Fifty-nine patients who ranged in age from 3.3 to 15.9 years (median, 10.1 years) received HLA-identical sibling marrow allografts between September 1991 and April 2000. Fifty-five patients survive, and 50 survive free from sickle cell disease, with a median follow-up of 42.2 months (range, 11.8 to 115 months) after transplantation. Of the 50 patients with successful allografts, 13 developed stable mixed donor-host hematopoietic chimerism. The level of donor chimerism, measured > or =6 months after transplantation in peripheral blood, varied between 90% and 99% in 8 patients. Five additional patients had a lower proportion of donor cells (range, 11% to 74%). Among these 5 patients, hemoglobin levels varied between 11.2 and 14.2 g/dL (median, 11.3 g/dL; mean, 12.0 g/dL). In patients who had donors with a normal hemoglobin genotype (Hb), the Hb S fractions were 0%, 0%, and 7%, corresponding to donor chimerism levels of 67%, 74%, and 11%, respectively. Among patients who had donors with sickle trait, the Hb S fractions were 36% and 37%, corresponding to donor chimerism levels of 25% and 60%, respectively. Thus, allograft recipients with stable mixed chimerism had Rb S levels similar to donor levels, and only 1 patient required a red blood cell transfusion beyond 90 days posttransplantation. None of the patients have experienced painful events or other clinical complications related to sickle cell disease after transplantation. These observations strongly suggest that patients with sickle cell disease who develop persistent mixed hematopoietic chimerism after transplantation experience a significant ameliorative effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Storb, R., Deeg, H. J., Whitehead, J., Appelbaum, F., Beatty, P., Bensinger, W., Buckner, C. D., Clift, R., Doney, K., Farewell, V., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198603203141201 · Cited by 1,411
Self-citationHill, G. R., Crawford, J. M., Cooke, K. R., Brinson, Y. S., Pan, L., & Ferrara, J. L. M. (1997) · Blood · doi:10.1182/blood.v90.8.3204 · Cited by 832
Cytokine dysregulation and acute graft-versus-host disease
Antin, J., & Ferrara, J. (1992) · Blood · doi:10.1182/blood.v80.12.2964.2964 · Cited by 662
Growth and decay of pulmonary function in healthy blacks and whites
Schoenberg, J. B., Beck, G. J., & Bouhuys, A. (1978) · Respiration Physiology · doi:10.1016/0034-5687(78)90063-4 · Cited by 396
Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions
Pegelow, C. H., Adams, R. J., McKie, V., Abboud, M., Berman, B., Miller, S. T., Olivieri, N., Vichinsky, E., Wang, W., & Brambilla, D. (1995) · The Journal of Pediatrics · doi:10.1016/s0022-3476(95)70204-0 · Cited by 367
Self-citationSickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure.
Powars, D., WEIDMAN, J. A., Odom‐Maryon, T., Niland, J. C., & Johnson, C. M. (1988) · PubMed · Cited by 329
Vermylen, C., Cornu, G., Ferster, A., Brichard, B., Ninane, J., Ferrant, A., Zenebergh, A., Maes, P., Dhooge, C., Benoit, Y., et al. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701291 · Cited by 260
Cited by
Kernan, W. N., Ovbiagele, B., Black, H. R., Bravata, D. M., Chimowitz, M. I., Ezekowitz, M. D., Fang, M. C., Fisher, M., Furie, K. L., Heck, D. V., et al. (2014) · Stroke · doi:10.1161/str.0000000000000024 · Cited by 5,170
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Furie, K. L., Kasner, S. E., Adams, R. J., Albers, G. W., Bush, R. L., Fagan, S. C., Halperin, J. L., Johnston, S. C., Katzan, I., Kernan, W. N., et al. (2011) · Stroke · doi:10.1161/str.0b013e3181f7d043 · Cited by 1,492
Gene therapy in a patient with sickle cell disease
Ribeil, J.-A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., El Nemer, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609677 · Cited by 696
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Circulation · doi:10.1161/circ.113.10.e409 · Cited by 541
Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease
Bernaudin, F., Socie, G., Kuentz, M., Chevret, S., Duval, M., Bertrand, Y., Vannier, J.-P., Yakouben, K., Thuret, I., Bordigoni, P., et al. (2007) · Blood · doi:10.1182/blood-2007-03-079665 · Cited by 515
DeWitt, M. A., Magis, W., Bray, N. L., Wang, T., Berman, J. R., Urbinati, F., Heo, S.-J., Mitros, T., Muñoz, D. P., Boffelli, D., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf9336 · Cited by 477
Self-citationAllogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell Disease
Hsieh, M. M., Kang, E. M., Fitzhugh, C. D., Link, M. B., Bolan, C. D., Kurlander, R., Childs, R. W., Rodgers, G. P., Powell, J. D., & Tisdale, J. F. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904971 · Cited by 455
Hsieh, M. M., Fitzhugh, C. D., Weitzel, R. P., Link, M. E., Coles, W. A., Zhao, X., Rodgers, G. P., Powell, J. D., & Tisdale, J. F. (2014) · JAMA · doi:10.1001/jama.2014.7192 · Cited by 353
Correction of the sickle cell disease mutation in human hematopoietic stem/progenitor cells
Hoban, M. D., Cost, G. J., Mendel, M. C., Romero, Z., Kaufman, M. L., Joglekar, A. V., Ho, M., Lumaquin, D., Gray, D., Lill, G. R., et al. (2015) · Blood · doi:10.1182/blood-2014-12-615948 · Cited by 320
Iannone, R., Casella, J. F., Fuchs, E. J., Chen, A. R., Jones, R. J., Woolfrey, A., Amylon, M., Sullivan, K. M., Storb, R. F., & Walters, M. C. (2003) · Biology of Blood and Marrow Transplantation · doi:10.1016/s1083-8791(03)00192-7 · Cited by 269
Self-citationInduction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus
Antoniani, C., Meneghini, V., Lattanzi, A., Felix, T., Romano, O., Magrin, E., Weber, L., Pavani, G., El Hoss, S., Kurita, R., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811505 · Cited by 194
Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease
Hoban, M. D., Orkin, S. H., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2015-09-618587 · Cited by 194
Genome editing of HBG1 and HBG2 to induce fetal hemoglobin
Métais, J.-Y., Doerfler, P. A., Mayuranathan, T., Bauer, D. E., Fowler, S. C., Hsieh, M. M., Katta, V., Keriwala, S., Lazzarotto, C. R., Luk, K., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000820 · Cited by 177
Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.
Brendel, C., Guda, S., Renella, R., Bauer, D. E., Canver, M. C., Kim, Y.-J., Heeney, M. M., Klatt, D., Fogel, J., Milsom, M. D., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87885 · Cited by 167
Hematopoietic Stem Cell Transplantation in Thalassemia and Sickle Cell Anemia
Lucarelli, G., Isgro, A., Sodani, P., & Gaziev, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a011825 · Cited by 166
Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β A(T87Q) - Globin Gene
Negre, O., Eggimann, A.-V., Beuzard, Y., Ribeil, J.-A., Bourget, P., Borwornpinyo, S., Hongeng, S., Hacein-Bey, S., Cavazzana, M., Leboulch, P., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.007 · Cited by 159
Hsieh, M. M., Bonner, M., Pierciey, F. J., Uchida, N., Rottman, J., Demopoulos, L., Schmidt, M., Kanter, J., Walters, M. C., Thompson, A. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001330 · Cited by 152
Self-citationWeber, L., Frati, G., Felix, T., Hardouin, G., Casini, A., Wollenschlaeger, C., Meneghini, V., Masson, C., De Cian, A., Chalumeau, A., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay9392 · Cited by 140
Brendel, C., Negre, O., Rothe, M., Guda, S., Parsons, G., Harris, C., McGuinness, M., Abriss, D., Tsytsykova, A., Klatt, D., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.03.015 · Cited by 72
Sickle cell disease: time for a closer look at treatment options?
Sheth, S., Licursi, M., & Bhatia, M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12413 · Cited by 57
“Furthermore, many studies have shown that full scale, verbal and performance IQ is significantly lower in children (Wang et al, 2001; Steen et al, 2005; Hijmans et al, 2011) and adults (Vichinsky et al, 2010) with sickle cell disease than in controls (see Table I).”
BackgroundCRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges
Demirci, S., Leonard, A., Haro-Mora, J. J., Uchida, N., & Tisdale, J. F. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2018_331 · Cited by 50
Metadata
- Authors
- Walters, M. C., Patience, M., Leisenring, W., Rogers, Z. R., Aquino, V. M., Buchanan, G. R., Roberts, I. A. G., Yeager, A. M., Hsu, L., Adamkiewicz, T., Kurtzberg, J., Vichinsky, E., Storer, B., Storb, R., & Sullivan, K. M.
- Venue
- Biology of Blood and Marrow Transplantation
- Publisher
- Elsevier BV
- Published
- 2001-12
- Volume
- 7
- Issue
- 12
- Pages
- 665-673
- ISSN
- 1083-8791 (ISSN-L)
- OpenAlex
- W2151452421
- Cited by
- 324
- References
- 29
- FWCI
- 3.91
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.